India Glycols Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

India Glycols Ltd trades at ₹1,147, in a confirmed uptrend and 13 weeks into that stage. That is +17.6% against its own 200-day average. It sits at 97% of a 52-week range of ₹813 to ₹1,159. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.

Today the stock is in a confirmed uptrend — week 13 of stage 2, confirmed. At ₹1,147 it trades +17.6% versus its 200-day average and sits at 97% of its 52-week range (₹813–₹1,159).

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +2,880% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

India Glycols Ltd trades at 26.3× P/E, at the pricey end of its own range (91st percentile). Its long-run median P/E is 15.8×, measured across 9.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 26.3× is at the pricey end of its own range (91st percentile), against a long-run median of 15.8× measured over 9.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +17.1% against a +37.7% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +27.4%/yr price move, ~+15.5%/yr came from earnings growth and ~+11.9 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

India Glycols Ltd reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 13.0% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

4-Factor Sector Score

63.9/100 — rank 4 of 14 in Alcoholic Beverages · 96% evidence confidence

India Glycols Ltd scores 63.9 out of 100 against the 14 companies it is compared with in Alcoholic Beverages, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 20.1 + 15.9 + 12.3 + 15.6 = 63.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

India Glycols Ltd reported ₹976 Cr of revenue in the Mar 26 quarter, +13.1% year on year. That is the 4th straight quarter of year-on-year growth. Over 10 years it has compounded at 6.1% a year. The last full year, FY26, came in at ₹4,211 Cr. The last four reported quarters add to ₹4,210 Cr.

FY26 revenue came in at ₹4,211 Cr (+11.8% on the year), capping 10 years at 6.1% compound. The latest quarter (Mar 26) printed ₹976 Cr, +13.1% year on year — the 4th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +11.8% growth against the decade's 6.1% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +11.7% over the last 4 quarters against +13.1%/yr over the last 8 — stabilising; TTM profit +26.8% vs +30.1%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

India Glycols Ltd's operating margin is 17.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 4.8% to 15.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 17.0%, +0.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 4.8%–15.0%, and FY26's 15.0% is the top of that band — a record year.

Why the margin moved: operating margin went +0.1 pp year on year while gross margin went −0.6 pp — the gain came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

India Glycols Ltd earned ₹87.0 Cr of net profit in the Mar 26 quarter, +35.9% year on year. It is the 9th consecutive quarter of growth. Full-year FY26 profit was ₹293 Cr. That is 8.9% of the quarter's revenue. The same quarter a year earlier earned ₹64.0 Cr.

Mar 26 profit was ₹87.0 Cr, +35.9% year on year — the 9th consecutive quarter of growth. On the full year, FY26 printed ₹293 Cr (+26.8%).

Why profit moved: revenue contributed +13.1% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +26.7% vs revenue +11.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 225% of India Glycols Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹769 Cr of operating cash against ₹293 Cr of profit. After ₹819 Cr of capital spending, ₹−50.0 Cr was left as free cash.

FY26: operating cash of ₹769 Cr against reported profit of ₹293 Cr, leaving free cash of ₹−50.0 Cr after ₹819 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 225% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 225%: the cash cycle tightened 18 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 5.7× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

India Glycols Ltd's cash conversion cycle runs 47 days in FY26, down from 65 days in FY21. Capital spending ran ₹2,120 Cr over the last 3 years. At FY26 sales of ₹4,211 Cr each day of that cycle holds about ₹11.5 Cr, so roughly ₹542 Cr sits inside the business at any moment.

FY26: debtors at 30 days, inventory at 139 days — roughly 4.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 47 days, tighter than FY21's 65.

The full loop: cash goes out to suppliers and production on day 0; stock waits 139 days to sell; customers pay about 30 days after that; and suppliers themselves are paid at 123 days — netting out to the 47-day cycle.

In money terms: at FY26 sales of ₹4,211 Cr, each day of the cycle holds about ₹11.5 Cr — so the 47-day loop keeps roughly ₹542 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹2,120 Cr over the last 3 fiscal years against ₹371 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹37.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

India Glycols Ltd earns a ROCE of 12% in FY26. That is up from a trough of 3% in FY15. Return on invested capital clears the cost of that capital by −3.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 7.0% net margin on 0.65× asset turns.

FY26 ROCE is 12%, recovered from a FY15 trough of 3% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 7.0% net margin × 0.65× asset turns × 2.22× balance-sheet leverage ≈ 10.1% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 8.8% − 12.0% = a −3.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

India Glycols Ltd carries total debt of ₹1,691 Cr against shareholder equity of ₹2,933 Cr as of Mar 26, a debt-to-equity of 0.58. On the annual view that ratio went from 0.59 in FY22 to 0.58 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹1,691 Cr against shareholder equity of ₹2,933 Cr — a debt-to-equity of 0.58. On the annual view, debt-to-equity went from 0.59 (FY22) to 0.58 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 5.1 points of India Glycols Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 5.2% of the company. Promoters moved −1.4 points over the same window, to 59.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +5.1 points over 8 quarters to 5.2%; Promoters: −1.4 points over 8 quarters to 59.6%; Foreign institutions: +0.5 points over 8 quarters to 2.2%.

Why the register moved: domestic institutions drove it (+5.1 points), absorbed on the other side by promoters (−1.4 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

India Glycols Ltd: the Z-score reads 2.29. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 2.29 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 2.29.

Frequently asked questions